Varenicline for smoking cessation in light smokers

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Introduction:: As the prevalence of cigarette smoking has declined, the proportion of smokers who smoke less than 10 cigarettes/day (cpd) has increased. Varenicline may provide an effective pharmacotherapeutic treatment option for increasing smoking abstinence rates among light smokers. Methods:: We conducted a randomized, placebo-controlled clinical trial evaluating the efficacy of varenicline for increasing smoking abstinence rates among light smokers (5-10 cpd). Participants received varenicline or placebo for 12 weeks. Outcomes were assessed at 3 and 6 months. Results:: Ninety-three participants were randomized. Fifty-two percent of participants terminated the study early. At end-of-treatment (3 months), the point prevalence smoking abstinence rate was 53.3% in the varenicline group compared to 14.5% in placebo (odds ratio [OR]: 6.69, 95% confidence interval [CI]: 2.48-18.06, P < .001), and the prolonged smoking abstinence rate was 40.0% and 8.3%, respectively (OR: 7.33, 95% CI: 2.24-23.98, P = .001). At end-of-study (6 months), the point prevalence smoking abstinence rate was 40.0% in the varenicline group compared to 20.8% in placebo (OR: 2.53, 95% CI: 1.01-6.34, P = .047), and the prolonged smoking abstinence rate was 31.1% and 8.3%, respectively (OR: 4.97, 95% CI: 1.49-16.53, P = .009). The estimated magnitude of the treatment effect remained consistent across the various missing data assumptions and in analyses that adjusted for gender. Nausea and sleep disturbance were more commonly reported in the varenicline group. Conclusions:: Varenicline was safe and effective for increasing long-term smoking abstinence rates in a population of predominantly White light cigarette smoker. The efficacy of varenicline in this study was comparable to that observed in heavier smokers. Implications:: Our findings demonstrate that varenicline is effective for increasing smoking cessation in light smokers. Our findings have implications for advancing the treatment of light smokers in clinical practice.

Original languageEnglish (US)
Pages (from-to)2031-2035
Number of pages5
JournalNicotine and Tobacco Research
Volume18
Issue number10
DOIs
StatePublished - Oct 1 2016

Fingerprint

Smoking Cessation
Smoking
Odds Ratio
Placebos
Confidence Intervals
Tobacco Products
Varenicline
Therapeutics
Smoke
Nausea
Sleep
Randomized Controlled Trials
Light

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Varenicline for smoking cessation in light smokers. / Ebbert, Jon Owen; Croghan, Ivana T; Hurt, Ryan T; Schroeder, Darrell R.; Hays, James Taylor.

In: Nicotine and Tobacco Research, Vol. 18, No. 10, 01.10.2016, p. 2031-2035.

Research output: Contribution to journalArticle

@article{2fb1dc4c33ae490ab63c470de5efa151,
title = "Varenicline for smoking cessation in light smokers",
abstract = "Introduction:: As the prevalence of cigarette smoking has declined, the proportion of smokers who smoke less than 10 cigarettes/day (cpd) has increased. Varenicline may provide an effective pharmacotherapeutic treatment option for increasing smoking abstinence rates among light smokers. Methods:: We conducted a randomized, placebo-controlled clinical trial evaluating the efficacy of varenicline for increasing smoking abstinence rates among light smokers (5-10 cpd). Participants received varenicline or placebo for 12 weeks. Outcomes were assessed at 3 and 6 months. Results:: Ninety-three participants were randomized. Fifty-two percent of participants terminated the study early. At end-of-treatment (3 months), the point prevalence smoking abstinence rate was 53.3{\%} in the varenicline group compared to 14.5{\%} in placebo (odds ratio [OR]: 6.69, 95{\%} confidence interval [CI]: 2.48-18.06, P < .001), and the prolonged smoking abstinence rate was 40.0{\%} and 8.3{\%}, respectively (OR: 7.33, 95{\%} CI: 2.24-23.98, P = .001). At end-of-study (6 months), the point prevalence smoking abstinence rate was 40.0{\%} in the varenicline group compared to 20.8{\%} in placebo (OR: 2.53, 95{\%} CI: 1.01-6.34, P = .047), and the prolonged smoking abstinence rate was 31.1{\%} and 8.3{\%}, respectively (OR: 4.97, 95{\%} CI: 1.49-16.53, P = .009). The estimated magnitude of the treatment effect remained consistent across the various missing data assumptions and in analyses that adjusted for gender. Nausea and sleep disturbance were more commonly reported in the varenicline group. Conclusions:: Varenicline was safe and effective for increasing long-term smoking abstinence rates in a population of predominantly White light cigarette smoker. The efficacy of varenicline in this study was comparable to that observed in heavier smokers. Implications:: Our findings demonstrate that varenicline is effective for increasing smoking cessation in light smokers. Our findings have implications for advancing the treatment of light smokers in clinical practice.",
author = "Ebbert, {Jon Owen} and Croghan, {Ivana T} and Hurt, {Ryan T} and Schroeder, {Darrell R.} and Hays, {James Taylor}",
year = "2016",
month = "10",
day = "1",
doi = "10.1093/ntr/ntw123",
language = "English (US)",
volume = "18",
pages = "2031--2035",
journal = "Nicotine and Tobacco Research",
issn = "1462-2203",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Varenicline for smoking cessation in light smokers

AU - Ebbert, Jon Owen

AU - Croghan, Ivana T

AU - Hurt, Ryan T

AU - Schroeder, Darrell R.

AU - Hays, James Taylor

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Introduction:: As the prevalence of cigarette smoking has declined, the proportion of smokers who smoke less than 10 cigarettes/day (cpd) has increased. Varenicline may provide an effective pharmacotherapeutic treatment option for increasing smoking abstinence rates among light smokers. Methods:: We conducted a randomized, placebo-controlled clinical trial evaluating the efficacy of varenicline for increasing smoking abstinence rates among light smokers (5-10 cpd). Participants received varenicline or placebo for 12 weeks. Outcomes were assessed at 3 and 6 months. Results:: Ninety-three participants were randomized. Fifty-two percent of participants terminated the study early. At end-of-treatment (3 months), the point prevalence smoking abstinence rate was 53.3% in the varenicline group compared to 14.5% in placebo (odds ratio [OR]: 6.69, 95% confidence interval [CI]: 2.48-18.06, P < .001), and the prolonged smoking abstinence rate was 40.0% and 8.3%, respectively (OR: 7.33, 95% CI: 2.24-23.98, P = .001). At end-of-study (6 months), the point prevalence smoking abstinence rate was 40.0% in the varenicline group compared to 20.8% in placebo (OR: 2.53, 95% CI: 1.01-6.34, P = .047), and the prolonged smoking abstinence rate was 31.1% and 8.3%, respectively (OR: 4.97, 95% CI: 1.49-16.53, P = .009). The estimated magnitude of the treatment effect remained consistent across the various missing data assumptions and in analyses that adjusted for gender. Nausea and sleep disturbance were more commonly reported in the varenicline group. Conclusions:: Varenicline was safe and effective for increasing long-term smoking abstinence rates in a population of predominantly White light cigarette smoker. The efficacy of varenicline in this study was comparable to that observed in heavier smokers. Implications:: Our findings demonstrate that varenicline is effective for increasing smoking cessation in light smokers. Our findings have implications for advancing the treatment of light smokers in clinical practice.

AB - Introduction:: As the prevalence of cigarette smoking has declined, the proportion of smokers who smoke less than 10 cigarettes/day (cpd) has increased. Varenicline may provide an effective pharmacotherapeutic treatment option for increasing smoking abstinence rates among light smokers. Methods:: We conducted a randomized, placebo-controlled clinical trial evaluating the efficacy of varenicline for increasing smoking abstinence rates among light smokers (5-10 cpd). Participants received varenicline or placebo for 12 weeks. Outcomes were assessed at 3 and 6 months. Results:: Ninety-three participants were randomized. Fifty-two percent of participants terminated the study early. At end-of-treatment (3 months), the point prevalence smoking abstinence rate was 53.3% in the varenicline group compared to 14.5% in placebo (odds ratio [OR]: 6.69, 95% confidence interval [CI]: 2.48-18.06, P < .001), and the prolonged smoking abstinence rate was 40.0% and 8.3%, respectively (OR: 7.33, 95% CI: 2.24-23.98, P = .001). At end-of-study (6 months), the point prevalence smoking abstinence rate was 40.0% in the varenicline group compared to 20.8% in placebo (OR: 2.53, 95% CI: 1.01-6.34, P = .047), and the prolonged smoking abstinence rate was 31.1% and 8.3%, respectively (OR: 4.97, 95% CI: 1.49-16.53, P = .009). The estimated magnitude of the treatment effect remained consistent across the various missing data assumptions and in analyses that adjusted for gender. Nausea and sleep disturbance were more commonly reported in the varenicline group. Conclusions:: Varenicline was safe and effective for increasing long-term smoking abstinence rates in a population of predominantly White light cigarette smoker. The efficacy of varenicline in this study was comparable to that observed in heavier smokers. Implications:: Our findings demonstrate that varenicline is effective for increasing smoking cessation in light smokers. Our findings have implications for advancing the treatment of light smokers in clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=84995685435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995685435&partnerID=8YFLogxK

U2 - 10.1093/ntr/ntw123

DO - 10.1093/ntr/ntw123

M3 - Article

VL - 18

SP - 2031

EP - 2035

JO - Nicotine and Tobacco Research

JF - Nicotine and Tobacco Research

SN - 1462-2203

IS - 10

ER -